Navigation Links
Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device
Date:3/12/2008

Innovative Device Utilizes Revolutionary Electrotherapy to Improve Healing

of Chronic Wounds

ALBUQUERQUE, New Mexico, March 12 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, today announced that its parent company, Belgium-based Kingfisher Healthcare, has received CE mark for its KFH Novo medical device, a breakthrough medical technology that enhances the healing of chronic wounds. KFH Novo is the latest addition to Kingfisher's line of safe, non-invasive energy therapies designed to treat patients suffering from a range of chronic conditions.

KFH Novo utilizes Kingfisher's revolutionary Bio-Electric Stimulation Therapy (BEST) to assist in and improve upon the healing of chronic wounds including venous leg ulcers, diabetic ulcers and pressure sores. This unique form of electrotherapy enhances the physiological processes of wound healing at a cellular level, increasing protein synthesis levels, stimulating angiogenesis and fibroblasts, and increasing levels of ATP production to restart and regenerate tissue healing.

"Treatments for chronic wounds remain a major clinical challenge as a significant number of patients endure painful, open abrasions for as long as a year," said Dr. Henk Snyman, founder and CEO of Kingfisher Healthcare. "We are thrilled to offer physicians and patients a safe, non-invasive and cost-effective therapy designed to successfully treat several types of chronic wounds."

Designed for home use, KFH Novo is portable, convenient and easy-to-use. Its sleek and modern design elements, including patented touch-screen panel, allows patients to monitor and control their treatments. KFH Novo is expected to enter the U.S. market in 2009.

"We are pleased to announce the addition of KFH Novo to our line of innovative, alternative therapies," said Herb Whitaker, CEO of Kingfisher Americas. "We look forward to working with the European medical community to introduce this unique therapy intended to significantly improve upon each patient's quality of life."

For more information on KFH Novo please visit http://www.kfhealth.com.

About Kingfisher Americas

Kingfisher Americas, a subsidiary of the Belgium-based Kingfisher Healthcare, is the first company to use safe, non-invasive energy to treat patients suffering from chronic conditions. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico, Kingfisher Americas focuses on establishing relationships with patients, patient support groups, and medical experts to improve the quality of life of fibromyalgia, post polio, and chronic fatigue syndrome patients. For more information, please visit http://www.kfamericas.com.


'/>"/>
SOURCE Kingfisher Americas
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kingfisher Healthcare Launches Breakthrough Product in Europe
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
7. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
11. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):